GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally.
Excellent balance sheet with acceptable track record.
Share Price & News
How has GNI Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3G6's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3G6 exceeded the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 3G6 exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is GNI Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is GNI Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3G6's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3G6's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3G6 is poor value based on its PE Ratio (259.9x) compared to the Biotechs industry average (40.7x).
PE vs Market: 3G6 is poor value based on its PE Ratio (259.9x) compared to the German market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3G6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3G6 is overvalued based on its PB Ratio (4.5x) compared to the DE Biotechs industry average (3.3x).
How is GNI Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GNI Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine GNI Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- GNI Group competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has GNI Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3G6 has high quality earnings.
Growing Profit Margin: 3G6 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 3G6 has become profitable over the past 5 years, growing earnings by 45.4% per year.
Accelerating Growth: 3G6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 3G6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 3G6's Return on Equity (4.8%) is considered low.
How is GNI Group's financial position?
Financial Position Analysis
Short Term Liabilities: 3G6's short term assets (¥10.2B) exceed its short term liabilities (¥3.2B).
Long Term Liabilities: 3G6's short term assets (¥10.2B) exceed its long term liabilities (¥4.3B).
Debt to Equity History and Analysis
Debt Level: 3G6's debt to equity ratio (12.8%) is considered satisfactory.
Reducing Debt: 3G6's debt to equity ratio has increased from 8.8% to 12.8% over the past 5 years.
Inventory Level: 3G6 has a low level of unsold assets or inventory.
Debt Coverage by Assets: 3G6's debt is covered by short term assets (assets are 6.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3G6 is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: 3G6 is profitable, therefore cash runway is not a concern.
What is GNI Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3G6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 3G6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3G6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3G6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3G6's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ying Luo (54yo)
Dr. Ying Luo, Ph.D. is Chairman, Chief Executive Officer and President of Cullgen Inc. Dr. Luo has been the Chief Executive Officer, President and Representative Executive Officer of GNI Group Ltd. since J ...
|CEO, President||10.83yrs||no data||3.27% ¥14.8m|
|Co-Founder||19.25yrs||no data||no data|
|Co-Founder||19.25yrs||no data||no data|
|Co-Founder||19.25yrs||no data||no data|
|CFO, Representative Executive Officer & Director||7.08yrs||no data||0.0048% ¥22.0k|
|Executive Officer & Director||no data||no data||0.0097% ¥43.9k|
Experienced Management: 3G6's management team is seasoned and experienced (19.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.
GNI Group Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: GNI Group Ltd.
- Ticker: 3G6
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥53.127b
- Listing Market Cap: JP¥453.808m
- Shares outstanding: 43.40m
- Website: https://www.gnipharma.com
Number of Employees
- GNI Group Ltd.
- Nihonbashi-Honcho YS Building
- 3rd Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|2160||TSE (The Tokyo Stock Exchange)||Yes||Common Stock||JP||JPY||Aug 2007|
|3G6||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2007|
|GNII.F||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Aug 2007|
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is Phase II clinical trial for the treatment of liver fibrosis, as well as F573, which is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/07 00:49|
|End of Day Share Price||2020/04/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.